|
|
|
| At the Bioprocessing Summit, August 18-21 in Boston, you'll explore cutting-edge science, share strategies with industry leaders, and address real-world challenges in bioprocess R&D, scale-up, quality, and analytics. From foundational science to emerging technologies, this is where the industry connects to learn, partner, and push the field forward. Learn more at BioprocessingSummit.com |
|
|
|
|
By Mark Tobolowsky and Michelle Butler — Hyman, Phelps & McNamara P.C. | The Commissioner's National Priority Voucher program is accepting applications. Experts predict brisk competition since the agency is only awarding five vouchers for now. | |
|
|
|
| The Evolution Of Nucleotide Production | Article | Roche CustomBiotech | From harsh chemicals to gentle enzymes: Explore the groundbreaking shift in nucleotide synthesis, making drug manufacturing cleaner, greener, and more efficient. |
|
|
| Breaking Through In Hematologic Malignancies | e-book | By Jen Vance and Greg Gregory, Precision for Medicine | Explore the hematology-oncology landscape and a strategic preview of the challenges and opportunities that are redefining care for blood cancers today. |
|
|
| The Way Forward: Supply Chain Solutions | Webinar | Thermo Fisher Scientific | Learn how to build a resilient supply chain to navigate today's complex environment. Expert speakers share insights on optimization, innovation, and strategic planning to meet evolving market conditions. |
|
|
|
|
By Erin Harris, Editor-In-Chief, Cell & Gene Follow Me On Twitter @ErinHarris_1 | Atsena Therapeutics exemplifies the field’s growing shift toward non-oncology indications with its targeted gene therapy for X-linked retinoschisis, a rare inherited retinal disorder with no approved treatments. | |
|
|
|
|
|
| 8 Critical Questions To Ask Your IRB | Article | BRANY | This article outlines eight essential questions to ask a potential IRB partner to assess their ability to help you navigate complex regulatory requirements while avoiding delays. |
|
|
CLINICAL TRIALS SOLUTIONS |
|
|
|
|
|
|
| Advancing the Future of Cell & Gene Therapy | This 11-12 November, Cell 2025 unites 1,000+ leading experts across the CGT value chain to solve key challenges, from scalable bioprocessing and regulatory hurdles to accelerating development timelines. Gain practical strategies across cell culture, therapy development, and CGT manufacturing, and hear from world-renowned leaders Bobby Gaspar (CEO, Orchard Therapeutics), Christof Von Kalle, (Director & BIH Chair, Research Clinic Luxemburg), and Dame Molly Stevens (University of Oxford). Register Now |
|
|
| Connect With Cell & Gene: |
|
|
|
